Bibliographic Details
| Title: |
Anti-pentraxin 3 antibodies and residual disease activity in rheumatoid arthritis. |
| Authors: |
Salvato, Mariangela, Frizzera, Francesca, Ghirardello, Anna, Calligaro, Antonia, Botsios, Costantino, Zen, Margherita, Doria, Andrea, Giollo, Alessandro |
| Source: |
Rheumatology; Apr2025, Vol. 64 Issue 4, p1672-1678, 7p |
| Subject Terms: |
CROSS-sectional method, BODY mass index, AUTOANTIBODIES, RHEUMATOID arthritis, ENZYME-linked immunosorbent assay, SEX distribution, BODY weight, SMOKING, FISHER exact test, SEVERITY of illness index, PREDNISONE, ABATACEPT, AGE distribution, MANN Whitney U Test, MULTIVARIATE analysis, STATURE, RESEARCH, ANALYSIS of variance, HEALTH outcome assessment, COMPARATIVE studies, TOCILIZUMAB, SOCIODEMOGRAPHIC factors, DATA analysis software, INFLAMMATION, TUMOR necrosis factors, RHEUMATOLOGISTS, GLUCOCORTICOIDS, REGRESSION analysis |
| Abstract: |
Objectives This study quantified anti-PTX3 antibodies in the serum of seropositive and seronegative RA patients, examining their associations with disease activity and patient-reported outcome measures (PROMs). Methods In this cross-sectional study, RA patients diagnosed per ACR/EULAR 2010 criteria were recruited. Seronegative RA was defined as ACPA <7 kU/L. Data on demographics, clinical characteristics, medications, and PROMs were collected. Serum anti-PTX3 antibodies were measured using an in-house ELISA method. Comparative analyses were conducted with historical controls having PsA and FM. Results The cohort included 83 RA patients (42 seropositive, 41 seronegative). Seropositive patients had lower anti-PTX3 antibody levels than PsA (P = 0.001) and FM (P = 0.004) controls. Seronegative patients had higher levels than seropositive ones (P = 0.032). Anti-PTX3 antibodies correlated with CDAI (r = 0.255), PtGA (r = 0.257), VAS-GH (r = −0.235), VAS-pain (r = 0.233), and HAQ (r = 0.311), but not with joint counts, inflammatory markers, or physician's global assessment. The PtGA association remained significant when adjusted for BMI, SJC28, ESR, and prednisone dosage (β = 0.206, P = 0.042). Patients with near-controlled RA (SJC28 ≤ 2, PtGA > 2) had higher anti-PTX3 levels than those with controlled disease (SJC28 ≤ 2, PtGA ≤ 2; P = 0.048). Tocilizumab or abatacept-treated patients had lower levels compared with those on TNFi or JAKi. Conclusion Elevated anti-PTX3 antibodies in RA indicate residual active disease despite controlled inflammation. They may serve as a biomarker for true active disease, especially in seronegative RA patients who might be undertreated. [ABSTRACT FROM AUTHOR] |
|
Copyright of Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
